News Archives

November 18, 2022

ASH 2021: Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Herpes Zoster Vaccine

As one ages, the risk of reactivating the zoster virus and developing a painful outbreak of shingles increases. While chickenpox was bad enough when you were a child, the adult form of herpes zoster or shingles can be much worse.

November 18, 2022

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

November 18, 2022

ASH 2021: Increased Risk for Serious Infections Linked with Monoclonal B-Cell Lymphocytosis

Patients with monoclonal B-cell lymphocytosis (MBL), a precursor to chronic lymphocytic leukemia (CLL), were at increased risk of severe infections, according to an analysis of records from participants collected in the Mayo Clinic Biobank.

November 18, 2022

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL / SLL.

November 14, 2022

CLL Society’s COVID-19 Update for the Week of November 14th, 2022

CLL Society’s COVID-19 Update for the Week of November 14th, 2022: Here is your weekly summary of what has been happening this past week in the United States. The variant picture continues to shift rapidly. Read more on this below.

November 14, 2022

Many Patients with Weak Immune Systems Don’t Realize Their COVID-19 Medicine Isn’t as Effective as It Used to Be

CNN interviewed CLL Society’s Dr. Brian Koffman and Robyn Brumble, RN, among others, to gain perspective on the significance of the diminishing susceptibility of the emerging SARS-CoV-2 Variants of Concern (VOC) to Evusheld, the only Pre-Exposure Prophylaxis (PrEP) for the immunocompromised; including all those with chronic lymphocytic leukemia/small lymphocytic

November 14, 2022

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

Our immune system is a complex organization of lymphocytes, myeloid cells (granulocytes, macrophages, dendritic cells), complement factors, cytokines, and other chemical mediators, which all work together to fend off disease and infection.

November 7, 2022

CLL Society’s COVID-19 Update for the Week of November 7th, 2022

CLL Society’s COVID-19 Update for the Week of November 7th, 2022: Here is your weekly summary of what has been happening this past week in the United States. The variant picture continues to shift rapidly. Read more on this below.

November 3, 2022

NCCN Revamps Treatment Preferences in CLL / SLL

In guidelines released in August 2022, the National Comprehensive Cancer Network (NCCN) moved zanubrutinib (Brukinsa) into the “preferred regimens” category for patients with CLL / SLL.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

ASH 2021: Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Herpes Zoster Vaccine

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Increased Risk for Serious Infections Linked with Monoclonal B-Cell Lymphocytosis

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

CLL Society’s COVID-19 Update for the Week of November 14th, 2022

Many Patients with Weak Immune Systems Don’t Realize Their COVID-19 Medicine Isn’t as Effective as It Used to Be

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

CLL Society’s COVID-19 Update for the Week of November 7th, 2022

NCCN Revamps Treatment Preferences in CLL / SLL

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT